CN105169149A - Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application - Google Patents
Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application Download PDFInfo
- Publication number
- CN105169149A CN105169149A CN201510702991.2A CN201510702991A CN105169149A CN 105169149 A CN105169149 A CN 105169149A CN 201510702991 A CN201510702991 A CN 201510702991A CN 105169149 A CN105169149 A CN 105169149A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- thyroid carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 87
- 208000024770 Thyroid neoplasm Diseases 0.000 title claims abstract description 62
- 201000002510 thyroid cancer Diseases 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000009825 accumulation Methods 0.000 title abstract description 6
- 238000011282 treatment Methods 0.000 claims description 54
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 52
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 52
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 40
- 208000026435 phlegm Diseases 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 241000195474 Sargassum Species 0.000 claims description 11
- 241000628997 Flos Species 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 20
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 241001474374 Blennius Species 0.000 abstract description 2
- 244000179560 Prunella vulgaris Species 0.000 abstract description 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000257739 Dioscorea bulbifera Species 0.000 abstract 1
- 235000008532 Dioscorea bulbifera Nutrition 0.000 abstract 1
- 244000167230 Lonicera japonica Species 0.000 abstract 1
- 235000017617 Lonicera japonica Nutrition 0.000 abstract 1
- 241000237502 Ostreidae Species 0.000 abstract 1
- 206010036790 Productive cough Diseases 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 210000003802 sputum Anatomy 0.000 abstract 1
- 208000024794 sputum Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 17
- 206010018498 Goitre Diseases 0.000 description 16
- 201000003872 goiter Diseases 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003172 expectorant agent Substances 0.000 description 11
- 230000003419 expectorant effect Effects 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000011287 therapeutic dose Methods 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 201000007227 lymph node tuberculosis Diseases 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- -1 bupleurumol Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940032091 stigmasterol Drugs 0.000 description 4
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 4
- 235000016831 stigmasterol Nutrition 0.000 description 4
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010013952 Dysphonia Diseases 0.000 description 3
- 208000010473 Hoarseness Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- IGJQUJNPMOYEJY-UHFFFAOYSA-N 2-acetylpyrrole Chemical compound CC(=O)C1=CC=CN1 IGJQUJNPMOYEJY-UHFFFAOYSA-N 0.000 description 2
- QPRQEDXDYOZYLA-UHFFFAOYSA-N 2-methylbutan-1-ol Chemical compound CCC(C)CO QPRQEDXDYOZYLA-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005242 forging Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- BCTBAGTXFYWYMW-UHFFFAOYSA-N linalool oxide pyranoside Chemical compound CC1(C)OC(C)(C=C)CCC1O BCTBAGTXFYWYMW-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 201000008440 thyroid gland anaplastic carcinoma Diseases 0.000 description 2
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 2
- 208000013076 thyroid tumor Diseases 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- UYALWPKCIMKALF-YHPVUIEZSA-N (1S,3R,5S,6R,8R,10R,11S,12S)-3-(furan-3-yl)-8-hydroxy-5-methyl-14-oxo-2,13-dioxatetracyclo[10.2.1.01,5.06,11]pentadecane-10-carboxylic acid Chemical compound C[C@@]12C[C@@H](O[C@@]11C[C@H](OC1=O)[C@@H]1[C@@H](C[C@H](O)C[C@@H]21)C(O)=O)c1ccoc1 UYALWPKCIMKALF-YHPVUIEZSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- YHGVYECWZWIVJC-MZGFOBBZSA-N (3s,4ar,6ar,6bs,8s,8as,12as,14ar,14br)-8a-(hydroxymethyl)-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-3,8-diol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YHGVYECWZWIVJC-MZGFOBBZSA-N 0.000 description 1
- 125000000545 (4R)-limonene group Chemical group 0.000 description 1
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 1
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- CPGCVOVWHCWVTP-LJAQVGFWSA-N (S)-nonacosan-10-ol Chemical compound CCCCCCCCCCCCCCCCCCC[C@@H](O)CCCCCCCCC CPGCVOVWHCWVTP-LJAQVGFWSA-N 0.000 description 1
- BRHDDEIRQPDPMG-PSASIEDQSA-N (±)-cis-Linalyl oxide Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(C=C)O1 BRHDDEIRQPDPMG-PSASIEDQSA-N 0.000 description 1
- BBOWBNGUEWHNQZ-MDZDMXLPSA-N 10E-nonadecenoic acid Chemical compound CCCCCCCC\C=C\CCCCCCCCC(O)=O BBOWBNGUEWHNQZ-MDZDMXLPSA-N 0.000 description 1
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- HSOCLPVBLYBQSN-UHFFFAOYSA-N 3-methyl-2-pent-1-enylcyclopent-2-en-1-one Chemical compound CCCC=CC1=C(C)CCC1=O HSOCLPVBLYBQSN-UHFFFAOYSA-N 0.000 description 1
- BXFMHHHDTOWXJZ-UHFFFAOYSA-N 8-hydroxy-3-methyl-1h-isochromen-4-one Chemical class C1=CC=C2C(=O)C(C)OCC2=C1O BXFMHHHDTOWXJZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- XMGQYMWWDOXHJM-JTQLQIEISA-N D-limonene Natural products CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 description 1
- QEANLIISUSNNDX-YHPVUIEZSA-N Diosbulbin B Chemical compound C=1([C@H]2C[C@@]3([C@@]4(C(O[C@@H](C4)[C@H]4[C@H]3C[C@@H]3C[C@H]4C(O3)=O)=O)O2)C)C=COC=1 QEANLIISUSNNDX-YHPVUIEZSA-N 0.000 description 1
- UYALWPKCIMKALF-UHFFFAOYSA-N Diosbulbin C Natural products O1C2(C(OC(C2)C2C3CC(O)CC2C(O)=O)=O)C3(C)CC1C=1C=COC=1 UYALWPKCIMKALF-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229920000305 Nylon 6,10 Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037168 Papillary Follicular Carcinoma Diseases 0.000 description 1
- CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000021738 Plummer disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- YHGVYECWZWIVJC-UHFFFAOYSA-N Primulagenin A Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CC(O)C5(CO)CCC(C)(C)CC5C4=CCC3C21C YHGVYECWZWIVJC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- YSKVBPGQYRAUQO-UZSYLJJSSA-N Schottenol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 YSKVBPGQYRAUQO-UZSYLJJSSA-N 0.000 description 1
- YSKVBPGQYRAUQO-UHFFFAOYSA-N Schottenol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 YSKVBPGQYRAUQO-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- CPGCVOVWHCWVTP-UHFFFAOYSA-N celidoniol Natural products CCCCCCCCCCCCCCCCCCCC(O)CCCCCCCCC CPGCVOVWHCWVTP-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- NETSQGRTUNRXEO-XUXIUFHCSA-N dehydrocostus lactone Chemical compound C([C@H]1C(=C)C(=O)O[C@@H]11)CC(=C)[C@H]2[C@@H]1C(=C)CC2 NETSQGRTUNRXEO-XUXIUFHCSA-N 0.000 description 1
- YSKVBPGQYRAUQO-UBCZCFGNSA-N delta7 Stigmastenol Natural products O[C@@H]1C[C@@H]2[C@@](C)([C@@H]3C([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)=CC2)CC1 YSKVBPGQYRAUQO-UBCZCFGNSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QEANLIISUSNNDX-UHFFFAOYSA-N diosbulbin B Natural products O1C2(C(OC(C2)C2C3CC4CC2C(O4)=O)=O)C3(C)CC1C=1C=COC=1 QEANLIISUSNNDX-UHFFFAOYSA-N 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- JYYFMIOPGOFNPK-AGRJPVHOSA-N ethyl linolenate Chemical compound CCOC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC JYYFMIOPGOFNPK-AGRJPVHOSA-N 0.000 description 1
- 229940090028 ethyl linolenate Drugs 0.000 description 1
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000021299 gondoic acid Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000020796 long term synaptic depression Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- BBOWBNGUEWHNQZ-UHFFFAOYSA-N nonadec-10-enoic acid Natural products CCCCCCCCC=CCCCCCCCCC(O)=O BBOWBNGUEWHNQZ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 1
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- AQWHMKSIVLSRNY-UHFFFAOYSA-N trans-Octadec-5-ensaeure Natural products CCCCCCCCCCCCC=CCCCC(O)=O AQWHMKSIVLSRNY-UHFFFAOYSA-N 0.000 description 1
- BRHDDEIRQPDPMG-UHFFFAOYSA-N trans-furanoid linalool oxide Natural products CC(C)(O)C1CCC(C)(C=C)O1 BRHDDEIRQPDPMG-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating the pyrophlegm stasis accumulation type thyroid cancer, a preparation method and application. The traditional Chinese medicine composition is prepared from, by weight, 6-12 parts of dioscorea bulbifera L, 6-12 parts of rhizoma Sparganii, 6-12 parts of radix glycyrrhizae, 10-20 parts of dried radix rehmanniae, 10-20 parts of radix scrophulariae, 4-9 parts of bupleurum, 6-12 parts of fried tangerine seed, 10-20 parts of snake gourd fruit, 10-20 parts of lonicera japonica, 10-20 parts of common selfheal fruit-spike, 10-20 parts of pericarpium citri reticulatae, 10-20 parts of seaweed, 10-20 parts of kelp and 20-40 parts of oyster. According to the formula, on the basis of comprehensive analysis on the thyroid cancer, according to the dialectical therapy principle, through the latest technology and means, through the combination of 30 years of clinical experience of hospitals and through trials and errors, the traditional Chinese medicine composition is developed, has a good curative effect on the later-period thyroid cancer, especially the undifferentiation type thyroid cancer, is mainly suitable for the pyrophlegm stasis accumulation type thyroid cancer, and has curative effects on eliminating sputum and softening hard mass, and promoting blood circulation to remove blood stasis.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of treat phlegm-fire stasis type thyroid carcinoma Chinese medicine composition and preparation method, application.
Background technology
Thyroid carcinoma is the modal malignant tumor of incidence, from pathology, mainly be divided into four types: papillary carcinoma, follicular carcinoma, medullary carcinoma and undifferentiated carcinoma, operation is its topmost therapeutic modality, can not the person of elimination for late tumor operation, papillary carcinoma and follicular carcinoma can adopt radionuclide therapy as differentiated thyroid carcinoma, medullary carcinoma and undifferentiated carcinoma are then of no curative effect the expectant treatment method of affirmative, especially undifferentiated carcinoma progress is fast, grade malignancy is high, and Most patients is dead in 6-10 month.
Thyroid carcinoma belongs to the traditional Chinese medical science " stony goiter " category, and the main pathogenesis of primary disease is stagnation of QI due to depression of the liver, dysfunction of the spleen in transportation, raw in phlegm-damp, stagnation of QI-blood, and phlegm-damp condensation throat, with the passing of time causes blood-vessel obstructive, with gas, expectorant, stasis of blood three combined into trouble.The disease of goiter, though have, the stagnation of QI, expectorant are solidifying, blood stasis is not, the intrinsic factor of its morbidity, is namely that human righteousness is weak.The generation of disease and human righteousness's close relation, due to positive QI-insufficiency, so that pathogenic factor is taken advantage of a weak point, knot gathers in meridians, internal organs, causes the pathological changes such as the stagnation of QI, expectorant are solidifying, blood stasis, leads to the disease of goiter.Its etiology and pathogenesis mainly contains three aspects: 1, the stagnation of QI: gas is the main manifestations of human body physiological function, is the important substance basis maintaining human life activity.As crossed because of diet partially or depressed, depressed emotion of being worried, making fate row not normal, functional disorder, forming the pathological phenomenon of the stagnation of QI, the stagnation of QI.Long-term depression and stagnation of QI, is polymerized to shape for a long time, causes lump to occur, and tying in throat is goiter due to disorder of QI.2, blood stasis: qi being the governor of blood, the stagnation of QI is hematogenous blockage then, stagnate with the passing of time, Ze Cheng Disorder tie lump, in cervical region be then stony goiter.3, expectorant coagulates: exopathogen is invaded and harassed, or feelings will internal injury, and has a delicate constitution, and multipotency makes mechanism of qi block, and body fluid gathers as expectorant.It is toxic goiter that expectorant is condensed in larynx both sides.
In a word, the origin cause of formation of thyroid carcinoma is that many factors causes, and other still have wet poly-, deficiency of the liver and kindey, heart-fire to recklessly act etc., and main be positive QI-insufficiency, exopathogen invade, so that the stagnation of QI, blood stasis, expectorant coagulate mutually cementing, form goiter.
Thyroid carcinoma mostly is phlegm-fire stasis type late period, and main manifestations is: cervical region wart arsine, partially hard in matter, in circle or oval, border is still clear, or matter is hard as stone, be difficult to pass, can be upper and lower with swallowing, with pharyngeal discomfort, or see the lower scrofula of chin, throat blocks, and swallows not smooth, very then hoarseness, suffocated breathing uncomfortable in chest, shape is thin thin, face is dim not damp, and thin fur or few, colour of the tongue purple is dim.Or having menoxenia, yellow, greasy and thin fur, body of the tongue is partially dark, stringy and rolling pulse.
For various reasons, the expectant treatment of thyroid carcinoma lacks effective method, especially undifferentiated carcinoma, and simple operative treatment is unsatisfactory, in the urgent need to finding novel Therapeutic Method.To the treatment of goiter, Chinese dynasties also have accumulated and compares rich experience, as Jin Dynasty ZHANG Cong-zheng proposes to prevent and treat goiter with Thallus Laminariae (Thallus Eckloniae), Sargassum, Thallus Laminariae (Thallus Eckloniae) in " Confucian's Duties to Their Parents ", Li Shizhen (1518-1593 A.D.) is loaded with by Rhizoma Dioscoreae Bulbiferae wine treatment goiter etc. in Compendium of Material Medica, so far these a few herbs are still the key medicine for the treatment of thyroid tumor, adopt and do not wane.More and more evidence shows, Chinese medicine can improve patient's immunity, fast track rehabilitation, prevents and delay recurrence and the transfer of thyroid carcinoma.
Thyroid carcinoma traditional Chinese medical herbal treatment relates generally to liver, spleen, dialectically should first distinguish excess and weakness of pathogen and vital QI relation, distinguishes the stagnation of QI and expectorant is tied, and distinguishes stagnation of liver-QI and insufficiency of the spleen.Disease in early days based on the domination of pathogen, namely with phlegm-damp cohesion, stagnation of QI due to depression of the liver for principal contradiction, now treatment should focus on liver-smoothing, qi-regulating, invigorating spleen to remove dampness reduces phlegm, the wart that disappears eliminating stagnation, to disappear, to attack; Middle and advanced stage thyroid cancer patients is due to the long-term consumption of disease, and healthy energy virtual loss is double accompanies the domination of pathogen, wherein based on healthy energy virtual loss, treatment should be noted the principle of strengthening vital QI to eliminate pathogenic factors, invigorating the spleen and benefiting QI, reinforcement and elimination in combination.Because of the stagnation of QI, expectorant coagulate, to stop up knot throat be the basic pathology that stony goiter is formed to blood stasis three, and some patients also shows as mental disorder pent-up, the strongly fragrant and pathological change of fire-transformation.Therefore primary disease is in the majority with excess syndrome person in early days, but sick then wasting QI-blood for a long time, cloudy essence is impaired, and often Sthenia is transforming into asthenia for disease, is wherein common with the deficiency of YIN, the deficiency of vital energy especially, so that becomes the syndrome of intermingled deficiency and excess that provide for the real in the unreal and for the unreal in the real.Be resolving phlegm and softening hard masses to the main rule for the treatment of of phlegm-fire stasis type thyroid carcinoma, blood circulation promoting and dispersing pathogen accumulation.
Summary of the invention
For the deficiencies in the prior art, the problem to be solved in the present invention is to provide a kind of Chinese medicine formula for the treatment of thyroid carcinoma, formula is carrying out on comprehensive analysis foundation to thyroid carcinoma, principle is treated according to dialectical, utilize state-of-the-art technology and means, in conjunction with hospital's more than 30 years clinical experience, develop through repetition test, to patients with late-stage thyroid carcinoma, especially undifferentiated type thyroid carcinoma has good therapeutic effect.Mainly be applicable to phlegm-fire stasis type thyroid carcinoma, the rule for the treatment of is resolving phlegm and softening hard masses, blood circulation promoting and dispersing pathogen accumulation.
For achieving the above object, the present invention adopts following technical scheme:
Treat a Chinese medicine composition for phlegm-fire stasis type thyroid carcinoma, be made up of the crude drug of following parts by weight:
Rhizoma Dioscoreae Bulbiferae 6-12 part, Rhizoma Sparganii 6-12 part, Radix Glycyrrhizae 6-12 part, Radix Rehmanniae 10-20 part, Radix Scrophulariae 10-20 part, Radix Bupleuri 4-9 part, stir-fry Fructus Citri tangerinae core 6-12 part, Fructus Trichosanthis 10-20 part, Flos Lonicerae 10-20 part, Spica Prunellae 10-20 part, Pericarpium Citri Reticulatae 10-20 part, Sargassum 10-20 part, Thallus Laminariae (Thallus Eckloniae) 10-20 part, Concha Ostreae 20-40 part.
Preferably, the Chinese medicine composition of above-described treatment phlegm-fire stasis type thyroid carcinoma, be made up of the crude drug of following parts by weight:
Rhizoma Dioscoreae Bulbiferae 7-11 part, Rhizoma Sparganii 7-11 part, Radix Glycyrrhizae 7-11 part, Radix Rehmanniae 12-18 part, Radix Scrophulariae 12-18 part, Radix Bupleuri 5-8 part, stir-fry Fructus Citri tangerinae core 7-11 part, Fructus Trichosanthis 12-18 part, Flos Lonicerae 12-18 part, Spica Prunellae 12-18 part, Pericarpium Citri Reticulatae 12-18 part, Sargassum 12-18 part, Thallus Laminariae (Thallus Eckloniae) 12-18 part, Concha Ostreae 25-35 part.
Preferably, the Chinese medicine composition of above-described treatment phlegm-fire stasis type thyroid carcinoma, be made up of the crude drug of following parts by weight:
Rhizoma Dioscoreae Bulbiferae 8 parts, Rhizoma Sparganii 8 parts, 8 parts, Radix Glycyrrhizae, 16 parts, the Radix Rehmanniae, Radix Scrophulariae 16 parts, Radix Bupleuri 6 parts, stir-fry Fructus Citri tangerinae core 8 parts, Fructus Trichosanthis 16 parts, Flos Lonicerae 16 parts, Spica Prunellae 16 Pericarpium Citri Reticulatae 16 parts, Sargassum 16 parts, Thallus Laminariae (Thallus Eckloniae) 16 parts, Concha Ostreae 30 parts.
The Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma of the present invention, is prepared into oral liquid, granule, capsule, drop pill, decoction or tablet etc. by the extract of each crude drug and pharmaceutically acceptable carrier and facilitates the clinical pharmaceutical dosage form taken.
When the extract of each raw material of the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention is made oral liquid, the extract adding distil water of each raw material is dissolved, filter, add syrup, adjust ph, make oral liquid.
When the extract of each raw material of the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention is made tablet, the extract of each raw material and lactose or corn starch, add magnesium stearate lubricant when needing, mix homogeneously, granulate, then tablet made by tabletting.
The extract of each raw material and carrier lactose or corn starch mix homogeneously when the extract of each raw material of the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention makes capsule, granulate, then encapsulatedly makes capsule.
When the extract of each raw material of the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention makes granule, the extract of each raw material and diluent lactose or corn starch mix homogeneously, granulate, dry, make granule.
The Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma of the present invention is preparing the application prevented and treated in thyroid carcinoma medicine.
The preparation method of the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention: the mixing of various crude drug is placed in extractor, extracts with water or hydrophilic solvent, concentrated extracting solution and get final product.
Described hydrophilic solvent is preferably selected from ethanol, methanol, acetone, butanediol or propylene glycol etc.
Described extraction can be the methods such as decoction, reflux, extract, dipping, percolation.
Specifically comprise the steps:
Get each taste crude drug by the parts by weight described in above-mentioned Chinese medicine composition, add crude drug 8-16 times water gaging, decoct and extract 2-3 time, each 30-60 minute, obtains decocting liquid, and being concentrated into decocting liquid proportion is 1.15-1.20---and when 40 DEG C, leave standstill 1-2 hour, obtain decoction.
Further, each crude drug is taken with the weight proportion described in above-mentioned Chinese medicine composition, be distributed in clean sandbag, then insert in retort and soak 1-1.5 hour, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filtering with 40-60 mesh sieve, is 0.1Kg/cm in steam pressure
2condition under, then concentrate decocting liquid with membrane evaporator, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, label, packaging, namely makes decoction.
Containing a certain amount of linalool, epoxylinalol in Flos Lonicerae of the present invention, after mixing with the medical material such as Rhizoma Dioscoreae Bulbiferae, Rhizoma Sparganii, decocting in process for a long time, be subject to high temperature, loss of volatile oil is comparatively large, therefore, in the present invention, preferred decocting time is 15 minutes, and decocting number of times is 2 times.
The present invention also provides a kind of Chinese medicine preparation be made up of above-mentioned Chinese medicine composition and excipient, and this Chinese medicine preparation can be solution, ointment, Emulsion or cream kind.Such as, in the concentrated solution of gained, add a certain amount of ethanol or polyhydric alcohol and appropriate antiseptic, can be made into the solution containing crude drug amount 50-500mg/ml.
The Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention, in side, Rhizoma Dioscoreae Bulbiferae, Sargassum, Thallus Laminariae (Thallus Eckloniae) dissipating phlegm and resolving masses softening the hard mass are monarch drug altogether, and Concha Ostreae, Spica Prunellae hard masses softening and resolving, removing heat-phlegm mutual reinforcement between are for using, Fructus Trichosanthis, Radix Platycodonis removing heat-phlegm, eliminating stagnation, Rhizoma Sparganii removing blood stasis disappears abdominal mass, is ministerial drug.Help with Radix Bupleuri, Pericarpium Citri Reticulatae promoting QI circulation for relieving depression, regulating functional activities of qi.The Radix Rehmanniae, Radix Scrophulariae have the merit of eliminating fire and detoxication, hard masses softening and resolving, are equipped with Flos Lonicerae eliminating carbuncle and dispel swollen.Radix Glycyrrhizae, Gan Wen, coordinating the actions of various ingredients in a prescription.
Rhizoma Dioscoreae Bulbiferae returns lung, Liver Channel, nature and flavor: bitter, pungent, salty, cool in nature, slightly poisonous.Obvious toxic-side effects is had to liver containing toxicity saponin, terpenoid.Chemical composition: containing diobulbine A, Saponin, tannin and starch.Partial desiccation tuber is containing sucrose 22.5%, reducing sugar 0.69%, starch 2.5%, Saponin, tannin.Also containing diosbulbin B, C and diosgenin.There is removing toxic substances and promoting subsidence of swelling, dissipating phlegm and resolving masses, effect of cooling blood for hemostasis.For thyromegaly, tuberculous lymphadenitis, laryngopharynx swelling and pain, spits blood, spitting of blood, pertussis, cancerous protuberance; Furuncle is controlled in external.To various types of goiter, all there is certain effect.Rhizoma Dioscoreae Bulbiferae wine like partly replacing surgical removal to thyroid tumor, for thyroid carcinoma, coordinates operative treatment, can improve curative effect.Eliminating stagnation disappears wart; Heat-clearing and toxic substances removing; Cooling blood for hemostasis.Main goiter, sore throat, carbuncle sore tumefacting virus, venom, tumor, haematemesis, epistaxis, spitting of blood, pertussis, lung-heat cough with asthma.
Rhizoma Sparganii returns liver, spleen channel, and property is pungent, bitter, flat, has removing blood stasis circulation of qi promoting, effect of removing food stagnancy pain relieving, for lump in the abdomen mass in the abdomen, and dysmenorrhea, blood stasis amenorrhea, obstruction of qi in the chest and cardialgia, food stagnation distending pain.Chemical analysis is phenethanol, hydroquinone, hexadecylic acid; also have totally 21 compositions such as dehydrocostuslactone, 3,4-dihydro-8-hydroxy-3-methyl-1H2-benzopyran-4-ones, 1-hydroxyl-2-acetyl group-4-methylbenzene, β elemene, 2-furan alcohol, 2-acetyl pyrrole.Again containing multiple organic acid: the acid of succinic acid, Rhizoma Sparganii, 9-11-octadecadienoic acid, 9-12-octadecadienoic acid, 10-nonadecenoic acid, 11-eicosenoic acid, benzoic acid, 3-benzene-2-acrylic acid, Azelaic Acid, decanedioic acid and the fatty acid containing C8-C10, C12, C14-C20.Also containing formoononetin, stigmasterol, cupreol, daucosterol etc.
Radix Glycyrrhizae property is sweet, flat, enters spleen, stomach, lung meridian.Have removing toxic substances, eliminate the phlegm, pain relieving, spasmolytic and antitumaous effect, in the traditional Chinese medical science, the removing toxic substances of Radix Glycyrrhizae energy invigorating the spleen and replenishing QI, nourishing the lung to arrest cough, emergency, hundred medicines that are in harmonious proportion.Modern medicine study shows, Radix Glycyrrhizae has antiviral, antiinflammatory, effect of protecting the liver, can be used for treating insufficiency of the spleen, cough and asthma, laryngopharynx swelling and pain, carbuncle pyogenic infections from tumour or sore etc.
The Radix Rehmanniae is sweet, cold.GUIXIN, liver, kidney channel.Main containing B-sitosterol and mannitol, and a small amount of stigmasterol, micro-campesterol, also containing rehmanin, alkaloid, fatty acid, catalpol, glucose and retinoid material; Root is again containing stachyose, arginine and r-Gamma Amino Butyric Acid.Have heat clearing away, promote the production of body fluid, moisturize, laxation, removing blood stasis with potent drugs, tissue regeneration promoting, pain relieving, regulating menstruation, removing heat from blood, anastalsis.
Sweet, salty, the micro-hardship of Radix Scrophulariae property, cold.Enter lung, stomach, kidney channel.There is effect of clearing away heat and cooling blood, eliminating fire and detoxication, hard masses softening and resolving.Normal cooperation Bulbus Fritillariae Uninbracteatae, the same use of Concha Ostreae, name says Xiao Lei Wan.Or suitably add Spica Prunellae, Thallus Laminariae (Thallus Eckloniae), the equivalent use of Sargassum.
Radix Bupleuri nature and flavor are bitter, be slightly cold, and return liver, gallbladder meridian.There is reconciling superficies and interior, effect of soothing the liver yang invigorating.Radix Bupleuri root is containing volatile oil, bupleurumol, oleic acid, linolenic acid, Palmic acid, stearic acid, carnaubic acid, glucose and Saponin etc.Markets Drug is had, saikoside unit F, E, G, longispinogenin in Saponin.Separately have report, separate saikoside in root and seed, this is the general name of multiple glycoside.In addition, hitodesterol, Δ 7-stigmastenol, Δ 22-stigmastenol, stigmasterol, adonite, Radix Angelicae Dahuricae element is contained in root.Stem, leaf are containing globulariacitrin.Fruit oil-containing 11.2%, wherein has petroselinic acid, petroselidic acid and sub-sleeve acid.Saikosaponin d gavage or lumbar injection have Tumor suppression growth to mice ehrlich carcinoma, and obviously can extend the life span of animal.Have the tumor necrosis factor of anticarcinogenic effect with the purebred white rabbit preparation of New Zealand with Radix Bupleuri, using hepatoma carcinoma cell as target cell, result makes cancer cellular necrosis, cracking.
Fry Fructus Citri tangerinae nuclearity bitter, flat, nontoxic.Enter liver, kidney channel.Regulate the flow of vital energy, eliminating stagnation, pain relieving.
Fructus Trichosanthis sweet in the mouth, cold in nature.Have lung moistening to eliminate the phlegm, the effect of promoting the circulation of QI the chest stuffiness relieving.Containing Saponin, organic acid and salt thereof, resin, fatty oil and pigment.The fatty oil amount of imitating is 26%, and wherein satisfied fatty acid accounts for 30%, and unsaturated fatty acid accounts for 66.5%, based on trichosanic acid.In addition, still containing pomegranate acid in seed oil, may be the special sheet composition in snake gourd seed oil.Also containing 4 △ 5-terpenoid in oil, 6 △ 7-terpenoid, are accredited as campesterol, 7,24-gallbladder steroid diene alcohol, 7,25-gallbladder steroid diene alcohol, 7,22,25-cholestatriene alcohol.And assign to the complete alcohol of bean steroid.1:5 Fructus Trichosanthis decoct can kill mouse ascites cancerous cell in vitro.The external anticancer effect of Pericarpium Trichosanthis is better than Semen Trichosanthis, and the strongest with 60% ethanol extraction effect.The noncrystal powder of off-white color obtained in the ether leachate of Pericarpium Trichosanthis also has anti-cancer effect in vitro, and animal experiment shows, Fructus Trichosanthis has certain inhibitory action to sarcoma.
Flos Lonicerae is sweet, micro-hardship, and delicate fragrance is pungent, cold.Return lung, stomach, the heart, large intestine channel.Containing chlorogenic acid, isochlorogenic acid, Ginnol, cupreol, stigmasterol, cupreol-D-Glucose glycoside, stigmasterol-D-Glucose glycoside, also containing volatile oil, its composition has linalool, left-handed-along trimethyl-2-vinyl-5-dihydroxy-tetrahydro pyrans, ethyl palmitate, 1, 1-di-thiacyclohexane, methyl linoleate, 3-methyl-2-(pentenyl)-2-cyclopentene-1-one, trans-anti-farnesol, ethyl linolenate, β-Bi clear casket oil alkene, cis-3-is alkene-1-alcohol, alpha-terpineol, Geraniol, benzyl benzoate, 2-methyl-butanol, benzyl alcohol, phenethanol, cis-linalool oxide, eugenol and carvacrol etc. tens of kinds.There are resisting pathogenic microbes effect, antiinflammatory and refrigeration function, the effect of booster immunization function, central excitation effect, blood fat reducing, antiendotoxin etc.Honeysuckle flower water and steeping in wine liquid have obvious lethal effect to tentative tumor cell.
Spica Prunellae is cold in nature, sweet in the mouth, pungent, micro-hardship.For the key medicine of clearing away liver-fire, Disperse hepatic depression, for scrofula, goiter, often join Concha Ostreae, Bulbus Fritillariae Thunbergii.Containing acidity many grain Polysaccharides from Prunella vulgaris L of tool anti human immune deficiency virus (HIV), it is also the Saponin of glycoside unit containing oleanolic acid, ursolic acid, oleanolic acid, globulariacitrin, hyperin, caffeic acid, vitamin C, D, D carotene, tannin and volatile oil.
Pericarpium Citri Reticulatae is warm in nature, acrid in the mouth, bitter in the mouth.Enter spleen channel, stomach warp, lung meridian.Regulating qi-flowing for strengthening spleen, in tune, dampness, reduces phlegm.Cure mainly distension and fullness in the abdomen or pain, the dyspepsia of stagnation of QI in spleen and stomach.Containing volatile oil, in oil, main component is D-limonene, beta-myrcene α-and nopinene etc., another containing the nor-dihydro Nobiletin of flavones ingredient hesperidin, neohesperidin, naringenin, dihydro Nobiletin and 5-.
Sargassum property is bitter, salty, cold.Return lung, spleen, kidney, liver stomach warp.There is effect of softening the hard mass, expectorant, diuretic, detumescent, cure mainly scrofula, goiter etc.Seaweed extracted liquor proteoglycan can resist various virus, comprising HIV (human immunodeficiency virus) and carcinogenic RNA viruses, has anticancer antivirus action.
Thallus Laminariae (Thallus Eckloniae) is salty, cold, returns liver, stomach, kidney channel.There is hard masses softening and resolving, expectorant, the function of diuretic, for goiter, scrofula.Containing algin element, mannitol, galactan, laminine, Thallus Laminariae (Thallus Eckloniae) polysaccharide, glutamic acid, aspartic acid, proline, vitamin B1, vitamin C, Citrin and iodine, potassium etc.
Concha Ostreae property is salty, is slightly cold.Return liver, gallbladder, kidney channel.Suppressing the hyperactive liver to relieve the wind syndrome and yin-nourishing drug, hard masses softening and resolving.Calcium carbonate containing 80% ~ 95%, calcium phosphate and calcium sulfate, and containing magnesium, aluminum, silicon and ferrum oxide etc.Concha Ostreae is containing glycogen, and taurine, 10 kinds of essential amino acids, glutathion, vitamin A, B1, B2, D, inanimate matter is as copper, zinc, manganese, barium, phosphorus and calcium etc., and wherein contained leucine, arginine, citrulline content are the abundantest.
The each flavour of a drug proportioning of full side, has the pathogenesis demonstrate,proved for thyroid carcinoma " phlegm-fire stasis ", reinforcement and elimination in combination, plays the merit of " resolving phlegm and softening hard masses, blood circulation promoting and dispersing pathogen accumulation " altogether, clinical evident in efficacy to thyroid carcinoma.
Beneficial effect: compared to the prior art the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention has the following advantages:
1, the medicine for the treatment of thyroid carcinoma of the present invention particularly above-mentioned Chinese medicine decoction, application modern crafts process, not only inhibition tumor cell growth diffusion, and anti-gene mutation, can also improve body's immunity, thus mitigation symptoms, extend patient vitals.
2, the medicine for the treatment of thyroid carcinoma of the present invention is for patients with late-stage thyroid carcinoma, especially the pathological characteristic of undifferentiated type thyroid carcinoma, the cost-effective therapeutic scheme of custom-designed one is treated in conjunction with differential diagnosis in tcm, can significantly improve symptom, reduce tumor and even make tumor disappearance, extend patient's life-span.
3, the present invention is according to Chinese medical theory, the theory of determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is adopted to carry out Chinese prescription screening, the Chinese medicine composition proportioning of the treatment phlegm-fire stasis type thyroid carcinoma provided is scientific and reasonable, experimental result shows, Chinese medicine composition provided by the invention has the effect well suppressing thyroid carcinoma cell growth and can promote apoptosis of tumor cells; There is raising immunity function, can obviously reduce tumor patient misery, extend life cycle, improve the effect of life in patients, and show through long-term experiment research, the Chinese medicine composition safety for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention is high, and toxic and side effects is low.
4, the extract of the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma provided by the invention, can facilitate and pharmaceutical carriers is prepared into multiple dosage form, taking convenience clinically.
Detailed description of the invention
The present invention is illustrated further below in conjunction with specific embodiment, these embodiments should be understood only be not used in for illustration of the present invention and limit the scope of the invention, after having read the present invention, the amendment of those skilled in the art to the various equivalent form of value of the present invention has all fallen within the application's claims limited range.
Embodiment 1
Each crude drug (unit in kilogram) is taken by following weight proportion
Preparation method is as follows: take each crude drug with the weight proportion described in prescription respectively, be distributed in clean sandbag, then insert in retort and soak 1-1.5 hour, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filtering with 40-60 mesh sieve, is 0.1Kg/cm in steam pressure
2condition under, then concentrate decocting liquid with membrane evaporator, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, label, packaging, namely makes decoction.
Instructions of taking: every day 1 dose, serve on 5 days, 5 doses weekly, having a rest 2 days, 4 weeks is a course for the treatment of.
Embodiment 2
Each crude drug (unit in kilogram) is taken by following weight proportion
Preparation method is as follows: take each crude drug with the weight proportion described in prescription respectively, be distributed in clean sandbag, then insert in retort and soak 1-1.5 hour, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filtering with 40-60 mesh sieve, is 0.1Kg/cm in steam pressure
2condition under, then concentrate decocting liquid with membrane evaporator, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, label, packaging, namely makes decoction.
Instructions of taking: every day 1 dose, serve on 5 days, 5 doses weekly, having a rest 2 days, 4 weeks is a course for the treatment of.
Embodiment 3
Each crude drug (unit in kilogram) is taken by following weight proportion
Preparation method is as follows: take each crude drug with the weight proportion described in prescription respectively, be distributed in clean sandbag, then insert in retort and soak 1-1.5 hour, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filtering with 40-60 mesh sieve, is 0.1Kg/cm in steam pressure
2condition under, then concentrate decocting liquid with membrane evaporator, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, label, packaging, namely makes decoction.
Instructions of taking: every day 1 dose, serve on 5 days, 5 doses weekly, having a rest 2 days, 4 weeks is a course for the treatment of.
Embodiment 4
Each crude drug (unit in kilogram) is taken by following weight proportion
Preparation method is as follows: take each crude drug with the weight proportion described in prescription respectively, be distributed in clean sandbag, then insert in retort and soak 1-1.5 hour, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filtering with 40-60 mesh sieve, is 0.1Kg/cm in steam pressure
2condition under, then concentrate decocting liquid with membrane evaporator, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, label, packaging, namely makes decoction.
Instructions of taking: every day 1 dose, serve on 5 days, 5 doses weekly, having a rest 2 days, 4 weeks is a course for the treatment of.
Embodiment 5
Each crude drug (unit in kilogram) is taken by following weight proportion
Preparation method is as follows: take each crude drug with the weight proportion described in prescription respectively, be distributed in clean sandbag, then insert in retort and soak 1-1.5 hour, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filtering with 40-60 mesh sieve, is 0.1Kg/cm in steam pressure
2condition under, then concentrate decocting liquid with membrane evaporator, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, label, packaging, namely makes decoction.
Instructions of taking: every day 1 dose, serve on 5 days, 5 doses weekly, having a rest 2 days, 4 weeks is a course for the treatment of.
Embodiment 6
Be, in preparation process with the difference of embodiment 1: Concha Ostreae is decocted first.Get Concha Ostreae, add Concha Ostreae 8 times of water yields, decoct after 15 minutes, again other crude drug medicine is put into simultaneously, add medical material 8 times of water yields, decocted 3 times respectively with 1 hour, 40 minutes, 30 minutes, merge 3 decocting liquids, filter with 40-60 mesh sieve, take steam pressure as 0.1Kg/cm2 condition, concentrate decocting liquid with membrane evaporator again, when being 1.15-1.20 (40 DEG C) to decocting liquid proportion, stop concentrated, leave standstill after 1-2 hour, by concentrated supernatant soft-packaged machine with therapeutic dose subpackage, conventional sterilant, labels, packaging, namely makes decoction.
Embodiment 7
Be with the difference of embodiment 1, preparation method is:
(1) get Concha Ostreae 24 parts, add medical material 15 times of water gagings, supersound extraction 3 times, each 3 hours, obtain Aqueous extracts, concentrated, n-butanol extraction, obtains butanol extraction liquid, upper macroporous resin column, rinse with water, then be 20 ~ 50% ethanol elutions by concentration, obtain alcohol eluen, vacuum drying, obtain Concha Ostreae extract, for subsequent use;
(2) get Rhizoma Dioscoreae Bulbiferae 7 parts, Rhizoma Sparganii 7 parts, 7 parts, Radix Glycyrrhizae, 10 parts, the Radix Rehmanniae, Radix Scrophulariae 10 parts, Radix Bupleuri 4 parts, fry Fructus Citri tangerinae core 7 parts, Fructus Trichosanthis 10 parts, Flos Lonicerae 10 parts, Spica Prunellae 10 parts, Pericarpium Citri Reticulatae 10 parts, Sargassum 10 parts, Thallus Laminariae (Thallus Eckloniae) 10 parts, add medical material 10 times amount concentration 60% alcohol heating reflux and extract three times, each 2 hours, merge extractive liquid, filter, filtrate recycling ethanol, concentrated, vacuum drying obtains extract, for subsequent use;
(3) extract that obtains of the Radix Codonopsis extract that obtains of combining step (1) and step (2), then add lactose, corn starch mix homogeneously, adds magnesium stearate lubricant, mix homogeneously, granulate, and then tablet made by tabletting.
Embodiment 8
In the medicine book in modern times, the record about Concha Ostreae mostly is life suppressing the hyperactive liver and subsiding YANG, forges with convergence astringent or styptic treatment for spontaneous sweating.Containing abundant ferrum, manganese, copper, zinc in Concha Ostreae, and returning of the content of trace element and Concha Ostreae has substantial connection through, effect.When adopting the decocting method process Concha Ostreae described in the embodiment of the present invention 1, experiment shows: Concha Ostreae is after forging, and the fried amount of zinc, copper increases, and especially after forging vinegar extraction, the fried amount of manganese, ferrum significantly increases.
Embodiment 9
Be with the difference of embodiment 1, in preparation process, decocting time is 15min, and decocting number of times is 2 times.
Embodiment 10
Clinical observation experiment
1.1 clinical data
1.1 physical data
Choose Shandong Tumor Hospital's outpatient service or ward and be diagnosed as late period and undifferentiated type thyroid cancer patients 298 example, male 157 example, women 141 example, 51.3 ± 6.00 years old mean age, the course of disease 4.32 ± 1.09 years;
1.2 Therapeutic Method
Taking the Traditional Chinese medicine compound composition that the embodiment of the present invention 1 prepares, usage: every day 1 dose, serve on 5 days, 5 doses weekly, have a rest 2 days, 4 weeks is a course for the treatment of.
1.3 therapeutic evaluation
Recovery from illness (complete incidence graph): body strengthens, antisecosis, transference cure, CT shows tumor and disappears completely after treatment, and the time is no less than 4 weeks.
Effectively (partial rcsponse): body strengthens, and muscle power comparatively treats front improvement, and symptom alleviates, CT shows tumor and reduce more than 50% after treatment, and the persistent period is no less than 4 weeks, occurs without new focus simultaneously.
Tumor stabilisation or unchanged: patient's muscle power comparatively before makes moderate progress, symptom without significant change, CT show tumor through treatment after reduce be no more than 50% or increase be no more than 25%.
Tumour progression: patient's physically-draining, exacerbation of symptoms, CT shows tumor and comparatively treats front increase or occur new focus.
2 therapeutic outcomes
Late period and undifferentiated type thyroid carcinoma 298 example, (5 doses weekly, serve on 5 days, has a rest 2 days to take Chinese medicine preparation of the present invention, within 4 weeks, be a course for the treatment of), applied for 3 courses for the treatment of, result shows: recovery from illness 9 example, effective 211 examples, stable disease 31 example, progress 46 example, total effective rate 84.6%.
The medicine particularly above-mentioned Chinese medicine decoction for the treatment of thyroid carcinoma of the present invention, application modern crafts process, not only inhibition tumor cell growth diffusion, and anti-gene mutation, can also improve body's immunity, thus mitigation symptoms, extend patient vitals.
Outcome measure
3 model cases
The outstanding effect of compound preparation in clinical treatment applying treatment thyroid carcinoma of the present invention is further illustrated below with model case.
Case 1 Wang, female, 45 years old, Heze City, Shandong Province people, finds that throat enclosed mass is gone to see a doctor with hoarseness for 1 month, is diagnosed as thyroid carcinoma and walks abreast operative treatment, because tumor invading carotid arteries and vitals fail thoroughly to excise, post operative diagnosis is anaplastic thyroid carcinoma.Take treatment by Chinese herbs of the present invention, pronounce comparatively and improve after 1 course for the treatment of, 3 CT check display course for the treatment of tumor disappearance, follow up a case by regular visits to half a year without recurrence.
Case 2 Lee, female, 65 years old, people from Dezhou, Shandong, because " Diagnosis of Cervical Masses 20 years; hoarseness 2 months " went to see a doctor, be diagnosed as thyroid malignancy, give excision, in art, find tumors invading and trachea and larynx, fail to excise completely for retaining larynx trachea function, Pathological diagnoses is anaplastic thyroid carcinoma.Take 3 courses for the treatment of of Chinese medicine preparation of the present invention, CT checks before tumor is comparatively taken medicine and reduces 80%, follows up a case by regular visits to 1 year tumor and has no continued growth.
In a word, the medicine for the treatment of thyroid carcinoma of the present invention is for patients with late-stage thyroid carcinoma, especially the pathological characteristic of undifferentiated type thyroid carcinoma, the cost-effective therapeutic scheme of custom-designed one is treated in conjunction with differential diagnosis in tcm, can significantly improve symptom, reduce tumor and even make tumor disappearance, extend patient's life-span.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (9)
1. treat a Chinese medicine composition for phlegm-fire stasis type thyroid carcinoma, it is characterized in that, be made up of the crude drug of following parts by weight:
Rhizoma Dioscoreae Bulbiferae 6-12 part, Rhizoma Sparganii 6-12 part, Radix Glycyrrhizae 6-12 part, Radix Rehmanniae 10-20 part, Radix Scrophulariae 10-20 part, Radix Bupleuri 4-9 part, stir-fry Fructus Citri tangerinae core 6-12 part, Fructus Trichosanthis 10-20 part, Flos Lonicerae 10-20 part, Spica Prunellae 10-20 part, Pericarpium Citri Reticulatae 10-20 part, Sargassum 10-20 part, Thallus Laminariae (Thallus Eckloniae) 10-20 part, Concha Ostreae 20-40 part.
2. the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma according to claim 1, is characterized in that, be made up of the crude drug of following parts by weight:
Rhizoma Dioscoreae Bulbiferae 7-11 part, Rhizoma Sparganii 7-11 part, Radix Glycyrrhizae 7-11 part, Radix Rehmanniae 12-18 part, Radix Scrophulariae 12-18 part, Radix Bupleuri 5-8 part, stir-fry Fructus Citri tangerinae core 7-11 part, Fructus Trichosanthis 12-18 part, Flos Lonicerae 12-18 part, Spica Prunellae 12-18 part, Pericarpium Citri Reticulatae 12-18 part, Sargassum 12-18 part, Thallus Laminariae (Thallus Eckloniae) 12-18 part, Concha Ostreae 25-35 part.
3. the Chinese medicine composition for the treatment of phlegm-fire stasis type thyroid carcinoma according to claim 1, is characterized in that, be made up of the crude drug of following parts by weight:
Rhizoma Dioscoreae Bulbiferae 8 parts, Rhizoma Sparganii 8 parts, 8 parts, Radix Glycyrrhizae, 16 parts, the Radix Rehmanniae, Radix Scrophulariae 16 parts, Radix Bupleuri 6 parts, stir-fry Fructus Citri tangerinae core 8 parts, Fructus Trichosanthis 16 parts, Flos Lonicerae 16 parts, Spica Prunellae 16, Pericarpium Citri Reticulatae 16 parts, Sargassum 16 parts, Thallus Laminariae (Thallus Eckloniae) 16 parts, Concha Ostreae 30 parts.
4. the preparation method of the Chinese medicine composition described in any one of Claim 1-3, is characterized in that, the mixing of various crude drug is placed in extractor, extracts with water or hydrophilic solvent, concentrated extracting solution and get final product.
5. preparation method as claimed in claim 4, it is characterized in that, described hydrophilic solvent is ethanol, methanol, acetone, butanediol or propylene glycol.
6. preparation method as claimed in claim 4, is characterized in that, specifically comprise the following steps:
Get each taste crude drug, add crude drug 8-16 times water gaging, decoct and extract 2-3 time, each 30-60 minute, obtains decocting liquid, and being concentrated into decocting liquid proportion is 1.15-1.20---and when 40 DEG C, leave standstill 1-2 hour, to obtain final product.
7. treat a Chinese medicine preparation for phlegm-fire stasis type thyroid carcinoma, it is characterized in that, be made up of the Chinese medicine composition described in any one of claim 1-3 and excipient.
8. Chinese medicine preparation according to claim 7, is characterized in that, it is oral liquid, granule, capsule, drop pill, decoction or tablet.
9. the Chinese medicine composition of the treatment phlegm-fire stasis type thyroid carcinoma described in any one of claims 1 to 3 is preparing the application prevented and treated in thyroid carcinoma medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510702991.2A CN105169149A (en) | 2015-10-26 | 2015-10-26 | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510702991.2A CN105169149A (en) | 2015-10-26 | 2015-10-26 | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105169149A true CN105169149A (en) | 2015-12-23 |
Family
ID=54891897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510702991.2A Pending CN105169149A (en) | 2015-10-26 | 2015-10-26 | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105169149A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878600A (en) * | 2016-05-19 | 2016-08-24 | 李丽丽 | Traditional Chinese medicine preparation for treating thyroid cancer and preparation method thereof |
| CN105902733A (en) * | 2016-05-19 | 2016-08-31 | 李丽丽 | Preparation with thyroid cancer resisting function for ultrasonography and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009057340A (en) * | 2007-09-03 | 2009-03-19 | Kyushu Univ | Cell growth inhibitor |
| CN103520507A (en) * | 2013-10-25 | 2014-01-22 | 王小薇 | Traditional Chinese medicine composition for treating thyroid cancer |
-
2015
- 2015-10-26 CN CN201510702991.2A patent/CN105169149A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009057340A (en) * | 2007-09-03 | 2009-03-19 | Kyushu Univ | Cell growth inhibitor |
| CN103520507A (en) * | 2013-10-25 | 2014-01-22 | 王小薇 | Traditional Chinese medicine composition for treating thyroid cancer |
Non-Patent Citations (1)
| Title |
|---|
| 王贞喜等: "甲状腺合剂制备与应用", 《时珍国医国药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878600A (en) * | 2016-05-19 | 2016-08-24 | 李丽丽 | Traditional Chinese medicine preparation for treating thyroid cancer and preparation method thereof |
| CN105902733A (en) * | 2016-05-19 | 2016-08-31 | 李丽丽 | Preparation with thyroid cancer resisting function for ultrasonography and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101972338B (en) | Chinese medicinal preparation for treating infantile upper respiratory tract infection and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102784363A (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN102772737A (en) | Traditional Chinese medicine composition for treating liver cirrhosis and fibrosis and preparation method thereof | |
| CN103099833A (en) | Soft capsule helpful for relieving sports fatigue and delaying aging and preparation method thereof | |
| CN103041256B (en) | Chinese herb preparation for curing recurrent respiratory tract infection of children | |
| CN103041257B (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
| CN101884779A (en) | Siberian solomonseal rhizome composition for intervening sub-health state and preparation method thereof | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN104474472A (en) | Broadleaf holly leaf buccal tablet capable of reducing high blood pressure, high blood lipid and high blood glucose and production method of buccal tablet | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN103041255B (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
| CN104739941A (en) | Traditional Chinese medicine preparation for treating kidney-Yang deficiency type aciesis and preparation method thereof | |
| CN105125985A (en) | Chinese and western medicine compound preparation for treating senile chronic bronchitis and preparation method thereof | |
| CN104491529A (en) | Traditional Chinese medicine granule for treating II diabetes and preparation method thereof | |
| CN103845616A (en) | Pharmaceutical composition for eliminating inflammation and disinfecting | |
| CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
| CN103705856B (en) | For preventing the Chinese medicine composition of chemicotherapy acute radio-reaction | |
| CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof | |
| CN105770760A (en) | Preparation for treating gastric ulcer and preparation method thereof | |
| CN103041259B (en) | Chinese materia medica preparation for curing excessive phlegm, cough and respiratory tract infection of children | |
| CN105168847A (en) | Traditional Chinese medicine for treating helicobacter pylori infected peptic ulcer | |
| CN104623471A (en) | Traditional Chinese medicine emulsion for treating stomach and duodenal ulcer and preparation method thereof | |
| CN104352773A (en) | Traditional Chinese medicine preparation for treating chronic bronchitis and bronchial asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Wanjun Inventor after: Wang Liang Inventor after: Li Zengjun Inventor after: Hu Man Inventor after: Zou Shujuan Inventor after: Li Yufang Inventor after: Wang Zhiqi Inventor after: Li Ke Inventor after: Zhang Shuguang Inventor before: Chen Wanjun Inventor before: Zhang Shuguang Inventor before: Wang Liang Inventor before: The inventor has waived the right to be mentioned Inventor before: Li Zengjun Inventor before: Hu Man Inventor before: Zou Shujuan Inventor before: Li Yufang Inventor before: Wang Zhiqi Inventor before: Li Ke |
|
| COR | Change of bibliographic data | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Wanjun Inventor after: Zhang Shuguang Inventor after: Wang Liang Inventor after: Wu Changhua Inventor after: Li Zengjun Inventor after: Hu Man Inventor after: Zou Shujuan Inventor after: Li Yufang Inventor after: Wang Zhiqi Inventor after: Li Ke Inventor before: Chen Wanjun Inventor before: Wang Liang Inventor before: Li Zengjun Inventor before: Hu Man Inventor before: Zou Shujuan Inventor before: Li Yufang Inventor before: Wang Zhiqi Inventor before: Li Ke Inventor before: Zhang Shuguang |
|
| COR | Change of bibliographic data | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151223 |
|
| RJ01 | Rejection of invention patent application after publication |